[New] CIA and DEA operations in Mexican territory, along with accusations against Mexican politicians accused of links to drug trafficking, will be intensified as a form of more direct intervention in national politics.
Mexico Solidarity Media
[New] A most-favored-nation pricing framework, which would peg US drug prices to lower international levels, poses a direct threat to Novo's US pricing power, where it generates a large portion of its revenue.
investing.com
[New] Eliminating the clinical equivalence study requirement for interchangeability could materially increase expected net present value in large biosimilar markets.
DrugPatentWatch - Transform Data into Market Domination
[New] Biosimilar adoption in the United States is increasing as more biologic drugs face patent expirations, creating significant opportunities for developers despite concerns about a future shortage of biosimilar candidates.
The Real Economy Blog
[New] Buyers remain interested, but they are taking more time on diligence, valuation and evaluating regulatory risk - including shifts in US policy related to drug pricing - and they are being more surgical about which assets justify a premium.
Financier Worldwide
[New] Antimicrobial resistance is a significant global health problem, with deaths from drug-resistant infections expected to exceed cancer by 2050.
Chemistry World
[New] Pharmaceutical sponsors are becoming more selective in vendor qualification, prioritizing manufacturers with strong compliance track records and global regulatory approvals to minimize the risk of supply disruption.
Persistence Market Research
[New] Fastest-Growing Service Type: Integrated CDMO services are expected to register a CAGR of around 9.1% from 2026 to 2033, owing to pharmaceutical companies consolidating vendors to accelerate development-to-commercialization timelines.
Persistence Market Research
[New] Leading Service Type: Drug substance manufacturing is expected to account for roughly 44% of revenue share in 2026, driven by increasing outsourcing of biologics and complex-molecule production, which require specialized infrastructure.
Persistence Market Research
[New] The Indian Pharmaceutical industry is projected to reach USD 130 billion by 2030 from USD 60 billion in 2026, showing rising future demand of precision fermentation technology.
Polaris
[New] The use of artificial intelligence in drug R&D will allow for quicker identification of targets, selection of candidates, and design of clinical trials.
tradingkey.com
[New] A share of nearly 63.2% is expected to be held by the U.S. in 2026, attributed to increasing research in DNA nanorobots, smart drug delivery systems, and AI-integrated nanomedical devices.
Persistence Market Research
Some 12% of Americans are taking a GLP-1 drug, helping convince millions of users and the many people who have watched their transformation that the key to health, beauty and longevity might come in a syringe.
Bloomberg
Injectable GLP-1 drugs turned Novo Nordisk and Eli Lilly into two of the most important pharmaceutical companies in the world, but injections were always going to limit adoption for some patients.
Windows Forum
In 2026, total prescription drug spending growth is expected to slow to a rate of 5.1% due to Inflation Reduction Act provisions.
Fortunly
Drug-resistant infections could contribute to 39 million deaths in the coming decades if effective interventions are not implemented.
Innovation News Network
Axios reports next month's weight-loss drug coverage program may unleash pent-up demand for Wegovy, Zepbound and other treatments, even as clinicians warn they do not have the staffing to absorb a prescribing rush.
MM+M - Medical Marketing and Media
European marketing authorisation is expected within weeks, and a US pivotal trial has been initiated with first data due in 2027 and a New Drug Application planned for 2028.
Business of Cannabis
Last updated: 14 July 2026
Hi,
Would you like a quick online demo of our service from an experienced member of our team?
